论文（近三年以通讯作者发表的SCI论文）

[1]Li TD, Sun GY, Ye H, Song CJ, Shen YJ, Cheng YF, Zou YL, Fang ZY, Shi JX, Wang KY, Dai LP, Wang P*. ESCCPred: A machine learning model for diagnostic prediction of early esophageal squamous cell carcinoma using autoantibody profiles. British Journal of Cancer, 2024, 131(5): 883-894.

[2]Sun GY, Ye H, Liu HJ, Li TD, Li JX, Zhang XY, Cheng YF, Wang KY, Shi JX, Dai LP, Wang P*. ZPR1 is an immunodiagnostic biomarker and promotes the tumor progression in esophageal squamous cell carcinoma. Cancer Science, 2024,115(1):70-822023.

[3]Liu HY, Li KM, Xia JF, Zhu JC, Cheng YF, Zhang XY, Ye H, Wang P*. Prediction of esophageal cancer risk based on genetic variants and environmental risk factors in Chinese population. BMC Cancer, 2024, 24(1): 598.

[4]Liu HY, Xu ZQ, Song CJ, Lu Y, Li TD, Zheng Z, Li M, Ye H, Wang KY, Shi JX, Wang P*. Burden of gastrointestinal cancers among people younger than 50 years in China, 1990 to 2019. Public Health, 2024, 234: 112-119.

[5]Zou YL, Zhu JC, Song CJ, Li TD, Wang KY, Shi JX, Ye H, Wang P*. A polygenetic risk score combined with environmental factors better predict susceptibility to hepatocellular carcinoma in Chinese population. Cancer Medicine, 2024, 13(9): e7230.

[6]Cheng YF, Li Q, Sun GY, Li TD, Zou YL, Ye H, Wang KY, Shi JX, Wang P*. Serum Anti-CFL1, Anti-EZR, and Anti-CYPA Autoantibody as Diagnostic Markers in Ovarian Cancer. Scientific Reports, 2024, 14(1): 9757.

[7]Zhang XY, Xie WH, Ye H, Zhu JC, Sun GY, Zhang YX, Sheng C, Li JX, Liu HY, Zheng Z, Wang P*. Mortality and disease burden of oral cancer in China: a time-trend analysis on the China Death Surveillance Database from 2006 to 2021. BMC Oral Health, 2024, 24(1): 938.

[8]Sun GY, Chen HL, Xia JF, Ye H, Li TD, Li JX, Zhang XY, Cheng YF, Wang KY, Shi JX, Wang P*. Diagnostic performance of anti-MAGEA family protein autoantibodies in esophageal squamous cell carcinoma. International Immunopharmacology, 2023, 125(Pt A): 111041.

[9]Yang Q, Ye H, Sun GY, Wang KY, Dai LP, Qiu CP, Shi JX, Zhu JC, Wang X, Wang P*. Human Proteome Microarray identifies autoantibodies to tumor-associated antigens as serological biomarkers for the diagnosis of hepatocellular carcinoma. Molecular Oncology, 2023, 17(5): 887-900.

[10]Sun GY, Ye H, Yang Q, Zhu JC, Qiu CP, Shi JX, Dai LP, Wang KY, Zhang JY, Wang P*. Using proteome microarray and gene expression omnibus database to screen tumour-associated antigens to construct the optimal diagnostic model of esophageal squamous cell carcinoma. Clinical Oncology, 2023, 35(10): e582-e592.

[11]Xie WH, Sui GY, Xia JX, Chen HL, Wang C, Lin J, Wang P*. Identification of novel tumor associated antigens and evaluation of a panel of autoantibodies in detecting oral cancer. BMC Cancer, 2023, 23(1): 802.

[12]Li JX, Chen HL, Sun GY, Zhang XY, Ye H, Wang P*. Role of miR-21 in the diagnosis of colorectal cancer: meta-analysis and bioinformatics. Pathology Research and Practice, 2023, 248: 154670.

[13]Chen HL, Sun GY, Han Z, Wang HM, Li JQ, Ye H, Song CH, Zhang JY, Wang P*. Anti-CXCL8 autoantibody：a potential diagnostic biomarker for esophageal squamous cell carcinoma. Medicina-Lithuania, 2022,58(10):1480.

[14]Xie WH, Sun GY, Zhu JC, Wang HM, Han Z, Wang P*. Anti-POSTN and anti-TIMP1 autoantibodies as diagnostic markers in esophageal squamous cell carcinoma. Frontiers in Genetics, 2022, 13: 860611.

[15]Li KM, Han Z, Wu JY, Ye H, Sun GY, Shi JX, Zhang JY, Wang P*. The Relationship between MALAT1 Polymorphism rs3200401 C > T and the Risk of Overall Cancer: A Meta-Analysis. Medicina-Lithuania, 2022,58(2):176.

著作

[1]王鹏（编委），罕见病临床与诊断(“十二五”国家科技支撑计划). 清华大学出版社（ISBN： 978-7-302-46614-7），2017.

[2]王鹏（编委、秘书），临床流行病学(医学高职高专“十二五”规划教材). 郑州大学出版社（ISBN：978-7-5645-1017-6），2012.

发明专利

[1]王鹏（第一发明人），一种用于食管鳞癌辅助诊断的生物标志物及检测试剂盒；专利号：ZL 2021 1 1294764.2

[2]王鹏（第二发明人），一种用于胃癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法；专利号：ZL 2019 1 1013212.2

[3]王鹏（第二发明人），一种用于食管鳞癌早期筛查和诊断的血清蛋白标志物、试剂盒及检测方法；专利号：ZL 2019 1 1014030.7